Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 18, Pages 6898-6903
Publisher
Proceedings of the National Academy of Sciences
Online
2012-04-17
DOI
10.1073/pnas.1204523109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- Unique modifications of translation elongation factors
- (2011) Eva Greganova et al. FEBS Journal
- Ankrd26Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts
- (2011) Zhaoliang Fei et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Resistance, epigenetics and the cancer ecosystem
- (2011) Stephen B Baylin NATURE MEDICINE
- MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1
- (2010) Sha Zhao et al. ARTHRITIS AND RHEUMATISM
- Reconstitution of Diphthine Synthase Activityin Vitro
- (2010) Xuling Zhu et al. BIOCHEMISTRY
- Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting
- (2010) E. Schafer et al. BLOOD
- Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia
- (2010) Francis Mussai et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake
- (2010) Y. Zhang et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia
- (2010) Kristjan Paulson et al. LEUKEMIA & LYMPHOMA
- Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1
- (2010) X. Du et al. MOLECULAR AND CELLULAR BIOLOGY
- How I treat patients with myelodysplastic syndromes
- (2009) R. M. Stone BLOOD
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia
- (2009) L Yánez et al. LEUKEMIA
- Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity
- (2008) X. Du et al. CANCER RESEARCH
- Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development
- (2008) T. R. Webb et al. JOURNAL OF CELL SCIENCE
- Progress in the Curative Treatment of Childhood Hematologic Malignancies
- (2008) Alan S. Wayne et al. JNCI-Journal of the National Cancer Institute
- Genome-scale DNA methylation maps of pluripotent and differentiated cells
- (2008) Alexander Meissner et al. NATURE
- Demethylating Agent 5-Aza-2′-Deoxycytidine Enhances Susceptibility of Bladder Transitional Cell Carcinoma to Cisplatin
- (2008) Donghao Shang et al. UROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now